Original InvestigationSafety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
This analysis was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Medical writing support was provided by Rob Campbell of Prime Medica Ltd., Knutsford, Cheshire, United Kingdom, supported by Sanofi and Regeneron Pharmaceuticals, Inc. Dr. Robinson has received research funding from Amarin, Amgen, AstraZeneca, Eli Lilly, Esai, GlaxoSmithKline, Merck, Pfizer, Regeneron Pharmaceuticals, Inc./Sanofi, and Takeda; and acted as a consultant and/or advisory panel member for Akcea/Ionis, Amgen, Eli Lilly, Esperion, Merck, Pfizer, and Regeneron/Sanofi. Dr. Rosenson has received research funding from Akcea, Amgen, AstraZeneca, Catabasis, The Medicines Company, Regeneron Pharmaceuticals, Inc., and Sanofi; and acted as a consultant and/or advisory board panel member for Akcea, Amgen, AstraZeneca, Eli Lilly, Regeneron Pharmaceuticals, Inc., and Sanofi. Dr. Farnier has received research support from and participated in a speakers bureau for Amgen, Merck, and Sanofi; has received honoraria from Abbott, Eli Lilly, and Pfizer; and acted as a consultant and/or advisory panel member for Amgen, Akcea/Ionis, AstraZeneca, Roche, Kowa, Merck, Mylan, Pfizer, Sanofi/Regeneron Pharmaceuticals, Inc., and Servier. Drs. Chaudhari and Merlet are stockholders and employees of Sanofi. Drs. Sasiela and Miller are stockholders and employees of Regeneron Pharmaceuticals, Inc. Dr. Kastelein has received consulting fees from Cerenis, The Medicines Company, CSL Behring, Amgen, Regeneron Pharmaceuticals, Inc., Eli Lilly, Esperion, AstraZeneca, Catabasis, UniQure, Novartis, Merck, Ionis Pharmaceuticals, Kowa, and Pfizer. P. K. Shah, MD, served as Guest Editor-in-Chief for this paper. Robert Giugliano, MD, SM, served as Guest Associate Editor for this paper.